Company intelligence / Profile preview
Airway Therapeutics
Atlanta, Georgia, United Statesairwaytherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Completed Phase 1b trial of zelpultide alfa (AT-100) with favorable safety profile in preterm neonates at risk for BPD. No dose-limiting toxicities were found and indications of efficacy were observed. Planning to launch a multinational Phase 3 trial in December 2024.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Biologics (recombinant human protein)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Airway Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Airway Therapeutics.